SCHEMBL18640901

SCHEMBL18640901

CC(C)(C)OC(=O)N1C(=O)NCC1c1ccc(F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
HRH3 Q9Y5N1 4/20 0.36
ADAMTS5 Q9UNA0 2/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
PRKCZ Q05513 2/20 0.35
RIPK1 Q13546 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PDE5A O76074 2/20 0.34
RORC P51449 1/20 0.34
P2RX7 Q99572 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18640934 0.86 RORC (0.39) PRKCZRIPK1PDE5ARORC
SCHEMBL18640948 0.84 RIPK1 (0.40) DPP4DDB1CRBNHRH3RIPK1
SCHEMBL18640891 0.82 NTRK1 (0.41)
SCHEMBL25007084 0.81 RIPK1 (0.36) DDB1CRBNRIPK1KDM4EMAPT
SCHEMBL18448056 0.81 RIPK1 (0.49) RIPK1RORCNR1H2NR1H3
SCHEMBL18640857 0.80 RIPK1 (0.42) RIPK1KDM4EMAPTTHRB
SCHEMBL18640858 0.80 TP53 (0.40) KDM4ESCN9A
SCHEMBL25327944 0.75 NR1H2 (0.38) DPP4ADAMTS5MMP2MMP13MMP14
SCHEMBL25327941 0.75 NR1H2 (0.38) DPP4ADAMTS5MMP2MMP13MMP14
SCHEMBL25914625 0.75 NR1H2 (0.38) DPP4ADAMTS5MMP2MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180237441-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-08-23 US disclosed
EP-3350185-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2018-07-25 EP disclosed
WO-2017046737-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-23 WO disclosed
WO-2017046737-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237441-A1 Chemical Compounds PSEN1, IRS1, CPT1A DPP4 4219/4885DDB1 1898/4885CRBN 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.